Research Breakthrough: A Two-Drug Combination Offers Hope
Small-cell lung cancer is an aggressive cancer most often treated with chemotherapy. But for patients whose cancer returns after treatment, there have been few effective options.
That may be about to change.
Moffitt researchers have recently completed a study showing that a combination of two immunotherapy drugs — nivolumab and ipilimumab — could offer a more effective treatment for small-cell lung cancer patients.
Scott J. Antonia, M.D., Ph.D., chair of the Department of Thoracic Oncology at Moffitt and first author of the study, explains how immunotherapy works:
“Immunotherapy differs from chemotherapy and radiation,” he says. “Because it uses the body’s own immune system to target and kill cancer cells, resulting in fewer side effects or quality of life disruptions for patients.”
The study showed particular promise for patients who had been resistant to chemotherapy, and for those who had already undergone chemotherapy more than once.
This encouraging research could lead to lives being saved.
And your support is helping to make it a reality. Thank you for making a real difference in the fight against cancer!